Project Grant R42DK141304
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$300K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), funds the development of novel, selective sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor compounds as a potential adjunctive therapy for cystic fibrosis (CF) associated metabolic disorders. The $613,558 award to Genetobe Inc., a Michigan-based biotechnology company, will...
This $195,625 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund a 2-year study to test whether AAV9-based GALT gene therapy can prevent long-term complications in a rat model of classic galactosemia. The goal is to evaluate the long-term biochemical and phenotypic efficacy of a single dose of scAAV9-hGALT administered intravenously to neonatal...
This federal Project Grant award of $253,500.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on developing selective degradation strategies to target mutant transcription factors. The research aims to address the problem of congenital dyserythropoietic anemia (CDA) caused by a single missense mutation in one allele of the KLF1 (EKLF)...
This federal Project Grant award, valued at $606,698.00 and awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the role of lysosomes in maintaining intestinal stem cells and their contribution to intestinal tumorigenesis. The key objectives of the project are to: 1) characterize the intestine-specific phenotypes of TFE3 and TFEB...
This $1,255,725 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of advanced manufacturing technologies for defined live microbial therapeutics. The key objectives are to: 1) Develop a solid-state fermentation platform to enable faster manufacturing timelines for defined live biotherapeutic products (LBPs) from months to...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $120,375 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, titled "Advanced Mouse Models of DDX41-Mutated Myelodysplastic Syndromes", will support the development of genetically-engineered mouse models to study the cellular and molecular mechanisms underlying myelodysplastic syndromes...
This $885,771 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is focused on developing new pharmacological inhibitors of the PFKFB3 enzyme. The goal is to restore cell fitness competition and eliminate dysfunctional beta-cells, thereby reversing the decline in beta-cell function that underlies the progression of type 2 diabetes. The project, awarded...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $675,480 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Fibrotherapeutics Inc. The funding supports the development of a novel, water-soluble, orally-active peptide derived from the caveolin-1 scaffolding domain (CSD) as a potential treatment for chronic kidney disease (CKD). The research aims to determine the therapeutic index, validate the...
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...